--- title: "WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/284068242.md" description: "WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) experienced a significant decline in short interest, dropping 82.6% to 24,485 shares as of April 15th. The short-interest ratio is currently 0.2 days, with approximately 0.0% of shares sold short. The stock traded at $8.54, with a 12-month range of $5.50 to $11.21. WuXi Biologics specializes in biologics as a global contract research and manufacturing organization, offering services across the biologics value chain." datetime: "2026-04-25T03:13:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284068242.md) - [en](https://longbridge.com/en/news/284068242.md) - [zh-HK](https://longbridge.com/zh-HK/news/284068242.md) --- # WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Short Interest Update WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the target of a significant decrease in short interest in April. As of April 15th, there was short interest totaling 24,485 shares, a decrease of 82.6% from the March 31st total of 140,652 shares. Currently, 0.0% of the company's stock are sold short. Based on an average daily volume of 107,227 shares, the days-to-cover ratio is presently 0.2 days. ## WuXi Biologics (Cayman) Price Performance Shares of OTCMKTS WXXWY traded down $0.01 during mid-day trading on Friday, reaching $8.54. The company had a trading volume of 32,840 shares, compared to its average volume of 63,502. The stock has a fifty day moving average of $9.22 and a two-hundred day moving average of $9.11. WuXi Biologics has a 12-month low of $5.50 and a 12-month high of $11.21. ## About WuXi Biologics (Cayman) (Get Free Report) WuXi Biologics (Cayman) Inc, trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies. The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors. ## See Also - Five stocks we like better than WuXi Biologics (Cayman) _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in WuXi Biologics (Cayman) Right Now? Before you consider WuXi Biologics (Cayman), you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WuXi Biologics (Cayman) wasn't on the list. While WuXi Biologics (Cayman) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) - [02359.HK](https://longbridge.com/en/quote/02359.HK.md) - [603259.CN](https://longbridge.com/en/quote/603259.CN.md) - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) ## Related News & Research - [Goldman Sachs Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)](https://longbridge.com/en/news/286522682.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL](https://longbridge.com/en/news/286523415.md) - [Alaunos Reports Preclinical Aln1003 Data Showing Effects On Insulin-Resistance-Related Biomarkers And Liver Histology In Diet-Induced Obesity Models](https://longbridge.com/en/news/286776760.md)